American Well (AMWL) Projected to Post Earnings on Wednesday

American Well (NYSE:AMWL) is anticipated to release its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect American Well to post earnings of ($1.59) per share and revenue of $52.7070 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

American Well Trading Up 5.6%

Shares of NYSE AMWL opened at $4.49 on Monday. American Well has a 1-year low of $3.71 and a 1-year high of $12.95. The company has a 50-day moving average of $4.62 and a two-hundred day moving average of $5.57. The company has a market cap of $73.47 million, a PE ratio of -0.62 and a beta of 1.36.

Analysts Set New Price Targets

Several research firms recently weighed in on AMWL. Wall Street Zen cut shares of American Well from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Wells Fargo & Company dropped their target price on American Well from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Morgan Stanley cut their price target on American Well from $10.50 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. Stifel Nicolaus lowered their price objective on American Well from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Wednesday, November 5th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of American Well in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $7.58.

Insiders Place Their Bets

In other American Well news, insider Dmitry Zamansky sold 6,243 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $4.85, for a total transaction of $30,278.55. Following the transaction, the insider owned 191,468 shares in the company, valued at approximately $928,619.80. This trade represents a 3.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 14,633 shares of company stock valued at $67,972 over the last quarter. Corporate insiders own 11.82% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Headlands Technologies LLC acquired a new position in American Well in the second quarter valued at about $39,000. Prelude Capital Management LLC bought a new position in shares of American Well during the 3rd quarter valued at about $86,000. Engineers Gate Manager LP acquired a new position in shares of American Well in the 2nd quarter valued at approximately $101,000. JPMorgan Chase & Co. increased its stake in American Well by 16.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 14,720 shares of the company’s stock worth $131,000 after purchasing an additional 2,081 shares in the last quarter. Finally, Norges Bank acquired a new stake in American Well during the 2nd quarter worth approximately $250,000. 56.05% of the stock is currently owned by institutional investors.

American Well Company Profile

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.